CN103504301A - 一种降压降糖降尿酸抗肿瘤的虾青素油的配方及制备方法 - Google Patents
一种降压降糖降尿酸抗肿瘤的虾青素油的配方及制备方法 Download PDFInfo
- Publication number
- CN103504301A CN103504301A CN201310455832.8A CN201310455832A CN103504301A CN 103504301 A CN103504301 A CN 103504301A CN 201310455832 A CN201310455832 A CN 201310455832A CN 103504301 A CN103504301 A CN 103504301A
- Authority
- CN
- China
- Prior art keywords
- astaxanthin
- edible oil
- oil
- capsule
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 title claims abstract description 119
- 239000001168 astaxanthin Substances 0.000 title claims abstract description 119
- 235000013793 astaxanthin Nutrition 0.000 title claims abstract description 119
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 title claims abstract description 119
- 229940022405 astaxanthin Drugs 0.000 title claims abstract description 119
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 238000009472 formulation Methods 0.000 title claims abstract description 7
- 239000000203 mixture Substances 0.000 title claims abstract description 7
- 230000000694 effects Effects 0.000 title abstract description 14
- 206010028980 Neoplasm Diseases 0.000 title abstract description 4
- 210000004369 blood Anatomy 0.000 title abstract description 4
- 239000008280 blood Substances 0.000 title abstract description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract description 3
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract description 3
- 229940116269 uric acid Drugs 0.000 title abstract description 3
- 230000036772 blood pressure Effects 0.000 title abstract 2
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 69
- 239000002775 capsule Substances 0.000 claims abstract description 25
- 239000003921 oil Substances 0.000 claims abstract description 24
- 238000007789 sealing Methods 0.000 claims abstract description 11
- 239000007963 capsule composition Substances 0.000 claims abstract description 10
- 239000012669 liquid formulation Substances 0.000 claims abstract description 7
- 201000005569 Gout Diseases 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims abstract description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 5
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 5
- 201000001421 hyperglycemia Diseases 0.000 claims abstract description 5
- 235000019198 oils Nutrition 0.000 claims description 23
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 16
- 230000000259 anti-tumor effect Effects 0.000 claims description 5
- 244000068988 Glycine max Species 0.000 claims description 4
- 235000010469 Glycine max Nutrition 0.000 claims description 4
- 235000019483 Peanut oil Nutrition 0.000 claims description 4
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 239000000312 peanut oil Substances 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- 238000002372 labelling Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 238000012856 packing Methods 0.000 abstract 1
- 230000032050 esterification Effects 0.000 description 5
- 238000005886 esterification reaction Methods 0.000 description 5
- 241000972773 Aulopiformes Species 0.000 description 4
- 235000021466 carotenoid Nutrition 0.000 description 4
- 150000001747 carotenoids Chemical class 0.000 description 4
- 235000019515 salmon Nutrition 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 241000195493 Cryptophyta Species 0.000 description 3
- 241000238557 Decapoda Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 229930195730 Aflatoxin Natural products 0.000 description 2
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000168517 Haematococcus lacustris Species 0.000 description 2
- 239000005409 aflatoxin Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- RASZIXQTZOARSV-BDPUVYQTSA-N astacin Chemical compound CC=1C(=O)C(=O)CC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)C(=O)CC1(C)C RASZIXQTZOARSV-BDPUVYQTSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 235000015170 shellfish Nutrition 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009184 walking Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000034498 Astacin Human genes 0.000 description 1
- 108090000658 Astacin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- FMKGDHLSXFDSOU-BDPUVYQTSA-N Dienon-Astacin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)C(=O)C(=CC1(C)C)O)C=CC=C(/C)C=CC2=C(C)C(=O)C(=CC2(C)C)O FMKGDHLSXFDSOU-BDPUVYQTSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 241000607153 Nipponia nippon Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 241000070023 Phoenicopterus roseus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000235342 Saccharomycetes Species 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N aldehydo-N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003676 astacin Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000002937 blood-testis barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000010742 number 1 fuel oil Substances 0.000 description 1
- 208000020717 oral cavity carcinoma Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种降压降糖降尿酸抗肿瘤的虾青素油的配方及制备方法,该配方包括虾青素食用油液体配方和虾青素食用油胶囊配方,液体配方中食用油与虾青素的重量比为100g:80mg;胶囊配方中食用油与虾青素的重量比为1000mg:100mg;虾青素食用油液体的制备方法为:按配方配比将虾青素倒入食用油中,搅拌溶解放置24小时装瓶,封口,贴标签,打码,装箱入库;其制备方法为:按配方将虾青素倒入食用油中搅拌均匀,放置24小时制成胶囊,每60粒一份装瓶,封口贴标签,打码装箱入库。胶囊中食用油与虾青素的重量比为1000mg:100mg可治疗痛风、高血糖、心脑血管病,食用油与虾青素的重量比为1000mg:400mg时抗肿瘤。本发明配方易掌握,工艺简单易操作,具有重要的推广意义。
Description
技术领域
本发明属于保健品领域,尤其涉及一种降压降糖降尿酸抗肿瘤的虾青素油的配方及制备方法。
背景技术
虾青素(英语:Astaxanthin,又称变胞藻黄素或虾红素),是类胡萝卜素的一种,为一种较强的天然抗氧化剂。与其他类胡萝卜素一样,虾青素属于一种脂溶性及水溶性的色素,在虾、蟹、鲑鱼、藻类等海洋生物中均可找到。虾青素的抗氧化能力强,为维他命E的550倍、β-胡萝卜素的10倍。因此,虾青素被包装为保健食品在市场发售。
虾青素是由几种藻类和浮游生物产生的,一些水生物种,包括虾在内的甲壳类动物都食用这些藻类和浮游生物,然后把这种色素储存在壳中,于是它们的外表呈现粉红色。这些贝壳类动物又被鱼(三文鱼,鳟鱼)和鸟(火烈鸟,朱鹭)捕食,然后把色素储存在皮肤和脂肪组织中。这就是三文鱼和其他一些动物呈现红色的原因。
不同的动物种属不同的组织器官虾青素分布不同,三文鱼的皮肤、鱼鳞、鱼籽以酯化态的虾青素为主,游离态的虾青素主要分布在肌肉、血浆和内脏器官。小虾体内以酯化虾青素为主。海鲤主要以酯化虾青素为主,主要在皮肤上。酯化的虾青素是储存在体内的更加稳定未被氧化过的虾青素。雨生红球藻(Haematococcus pluvialis)中主要就是酯化的虾青素,被公认为自然界中生产天然虾青素最好的生物。天然虾青素虽然存在多种生物体内,如虾壳、蟹壳、红色酵母菌内但含量均很低,提取工艺复杂。
虾青素作为一种最高效的纯天然抗氧化剂,最主要的功能是清除自由基,提高人体抗衰老能力。
天然虾青素能够穿透血脑屏障、血胰腺屏障、血睾丸屏障这三大人类主要屏障,并且是唯一能穿透血脑屏障的类胡萝卜素,因此是可能作用于脑细胞和眼球视网膜唯一一种类胡萝卜素。
虾青素能显著抑制化学物诱导的初期癌变,对暴露于致癌物质中的上皮细胞具有抗增殖作用和强化免疫功能的作用,如抑制膀胱癌、口腔癌、结肠癌、胃癌和乳腺癌的生长。虾青素还能降低黄曲霉毒素的致癌性,对减少黄曲霉毒素诱导的肝肿瘤细胞的数量和体积效果良好。
研究表明,虾青素很容易通过血脑屏障和细胞膜,能有效地防止视网膜的氧化和感光细胞的损伤,尤其是视网膜黄斑变性效果较叶黄素更加显著。对中枢神经系统尤其是对大脑起到保护作用,有效治疗缺血-再灌注损伤、脊髓损伤、帕金森综合征等中枢神经系统损伤。
紫外线辐射是导致表皮光老化和皮肤癌的重要原因,虾青素的强抗氧化性可能使它成为潜在的光保护剂,有效清除引起皮肤老化的自由基,保护细胞膜和线粒体膜免受氧化损伤,用于阻止皮肤光老化。
虾青素在体内具有显著升高HDL和降LDL的功效,其中HDL可由原来的49.7±3.6mg/dL增加至66.5±5.1mg/dL,因此推测虾青素能减轻载脂蛋白的氧化,可用来预防动脉硬化、冠心病和缺血性脑损伤。
虾青素能显著影响动物的免疫功能,在有抗原存在时,能明显促进脾细胞产生抗体的能力,增强T细胞的作用,刺激体内免疫球蛋白的产生。虾青素有很强的诱导细胞分裂的活性,具有重要的免疫调节作用。
虾青素可以作为一种抗氧化剂抑制自由基对机体的氧化损害作用。另外,口服虾青素还可以强化需氧代谢,增加肌肉力量和肌肉耐受力,迅速缓解运动疲劳,减轻剧烈运动后产生的迟发性肌肉疼痛。
如今,人们更加关注如何在日常生活中简单、绿色健康的自行制备虾青素保健制品。
发明内容
本发明实施例的目的在于提供一种降压降糖降尿酸抗肿瘤的虾青素油的配方及制备方法,旨在解决人们关注的如何在日常生活中简单、绿色健康的自行制备虾青素保健制品的问题。
本发明是这样实现的,一种降压降糖降尿酸抗肿瘤的虾青素油的配方,该配方包括虾青素食用油液体配方和虾青素食用油胶囊配方;
虾青素食用油液体配方中食用油与虾青素的重量比为100g:80mg;
虾青素食用油胶囊配方中食用油与虾青素的重量比为1000mg:100mg。
进一步,该配方中食用油可选用花生油、葵花籽油、豆油、橄榄油、葡萄籽油。
进一步,虾青素食用油胶囊配方中食用油与虾青素的重量比为也可为1000mg:400mg。
进一步,虾青素食用油胶囊中食用油与虾青素的重量比为1000mg:100mg时为治疗痛风,高血糖,心脑血管病配方。
进一步,虾青素食用油胶囊食用油与虾青素的重量比为1000mg:400mg时为抗肿瘤配方。
本发明的另一目的在于提供一种降压降糖降尿酸抗肿瘤的虾青素油的制备方法,该降压降糖降尿酸抗肿瘤的虾青素油的制备方法包括虾青素食用油液体的制备方法和虾青素食用油胶囊的制备方法;
1)虾青素食用油液体的制备方法为:按配方配比将虾青素倒入食用油中,搅拌溶解放置24小时装瓶,封口,贴标签,打码,装箱入库;
2)虾青素食用油胶囊的制备方法为:按配方将虾青素倒入食用油中搅拌均匀,放置24小时制成胶囊,每60粒一份装瓶,封口贴标签,打码装箱入库。
附图说明
图1是本发明实施例提供的降压降糖降尿酸抗肿瘤的虾青素油液体的制备方法流程图。
图2是本发明实施例提供的降压降糖降尿酸抗肿瘤的虾青素油胶囊的制备方法流程图。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
图1示出了本发明提供的降压降糖降尿酸抗肿瘤的虾青素油的配方及制备流程。为了便于说明,仅仅示出了与本发明相关的部分。
下面结合附图及具体实施例对本发明的应用原理作进一步描述。
虾青素食用油液体配方中食用油与虾青素的重量比为100g:80mg;
虾青素食用油胶囊配方中食用油与虾青素的重量比为1000mg∶100mg。
配方中食用油可选用花生油、葵花籽油、豆油、橄榄油、葡萄籽油。
虾青素食用油胶囊配方中食用油与虾青素的重量比为也可为1000mg:400mg。
虾青素食用油胶囊中食用油与虾青素的重量比为1000mg:100mg时治疗痛风,高血糖,心脑血管病。
虾青素食用油胶囊食用油与虾青素的重量比为1000mg:400mg时抗肿瘤。
虾青素食用油液体的制备方法为:按配方配比将虾青素倒入食用油中,搅拌溶解放置24小时装瓶,封口,贴标签,打码,装箱入库;
虾青素食用油胶囊的制备方法为:按配方将虾青素倒入食用油中搅拌均匀,放置24小时制成胶囊,每60粒一份装瓶,封口贴标签,打码装箱入库。
做成桶装,瓶装用于家庭生活使用;做成胶囊,早上饭后服用。
效果:降血压降尿酸降血糖抗肿瘤
实施例一:降血糖,降尿酸
1、备料:厨房用油(花生油,葵花籽油,豆油,橄榄油,葡萄籽油)100g,虾青素80mg
2、制作:将虾青素倒入食用油中,搅拌溶解放置24小时装瓶,封口,贴标签,打码,装箱入库。
3、疗效:患者食用虾青素两月余,血糖由原来的5.8降到4.5。尿酸(痛风)由原来的800降到450。
实施例二:治疗痛风、高血糖、心脑血管病
1、备料::食用油1000mg、虾青素100mg;。
2、制作方法:按配方将虾青素倒入食用油中搅拌均匀;放置24小时按制作工艺制成胶囊,每60粒一份装瓶,装并封口贴标签,打码装箱入库。
3、疗效:患者患有心血管疾病20多年并有心梗,未吃虾青素前行走200米就出现喘促、胸闷;食用虾青素食用油胶囊6个月,每天步行超过6000米,且未出现喘促、胸闷及乏力感。B超和血液检验提示各项指标均正常。
实施例三:抗肿瘤,延长肿瘤病人的寿命和生活质量
1、备料:食用油1000mg、虾青素400mg
2、制作胶囊:按配方将虾青素倒入食用油中搅拌均匀;放置24小时按制作工艺制成胶囊,每60粒一份装瓶,装并封口贴标签
3、疗效:胃溃疡患者,溃疡发作疼痛难忍,医生建议手术治疗。服用虾青素每天24mg至30mg,一个月后疼痛基本消失,观察病情未再发作胃痛。
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换和改进等,均应包含在本发明的保护范围之内。
Claims (6)
1.一种降压降糖降尿酸抗肿瘤的虾青素油的配方,其特征在于,该配方包括虾青素食用油液体配方和虾青素食用油胶囊配方;
虾青素食用油液体配方中食用油与虾青素的重量比为100g:80mg;
虾青素食用油胶囊配方中食用油与虾青素的重量比为1000mg:100mg。
2.如权利要求1所述的降压降糖降尿酸抗肿瘤的虾青素油的配方,其特征在于,该配方中食用油可选用花生油、葵花籽油、豆油、橄榄油、葡萄籽油。
3.如权利要求1所述的降压降糖降尿酸抗肿瘤的虾青素油的配方,其特征在于,虾青素食用油胶囊配方中食用油与虾青素的重量比为也可为1000mg:400mg。
4.如权利要求1所述的降压降糖降尿酸抗肿瘤的虾青素油的配方,其特征在于,虾青素食用油胶囊中食用油与虾青素的重量比为1000mg:100mg时为治疗痛风,高血糖,心脑血管病配方。
5.如权利要求1所述的降压降糖降尿酸抗肿瘤的虾青素油的配方,其特征在于,虾青素食用油胶囊食用油与虾青素的重量比为1000mg:400mg时为抗肿瘤配方。
6.一种降压降糖降尿酸抗肿瘤的虾青素油的制备方法,其特征在于,该降压降糖降尿酸抗肿瘤的虾青素油的制备方法包括虾青素食用油液体的制备方法和虾青素食用油胶囊的制备方法;
1)虾青素食用油液体的制备方法为:按配方配比将虾青素倒入食用油中,搅拌溶解放置24小时装瓶,封口,贴标签,打码,装箱入库;
2)虾青素食用油胶囊的制备方法为:按配方将虾青素倒入食用油中搅拌均匀,放置24小时制成胶囊,每60粒一份装瓶,封口贴标签,打码装箱入库。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310455832.8A CN103504301A (zh) | 2013-09-30 | 2013-09-30 | 一种降压降糖降尿酸抗肿瘤的虾青素油的配方及制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310455832.8A CN103504301A (zh) | 2013-09-30 | 2013-09-30 | 一种降压降糖降尿酸抗肿瘤的虾青素油的配方及制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN103504301A true CN103504301A (zh) | 2014-01-15 |
Family
ID=49888157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310455832.8A Pending CN103504301A (zh) | 2013-09-30 | 2013-09-30 | 一种降压降糖降尿酸抗肿瘤的虾青素油的配方及制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103504301A (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104644798A (zh) * | 2014-12-30 | 2015-05-27 | 天津天狮生物发展有限公司 | 一种预防缓解痛风及改善高尿酸血症的中药组合物 |
CN105901176A (zh) * | 2016-04-15 | 2016-08-31 | 安徽华安食品有限公司 | 一种糖尿病人专用调和油及其制备方法 |
CN107006622A (zh) * | 2017-04-06 | 2017-08-04 | 山东海葵生物科技有限公司 | 一种养生食用油及其制备方法 |
CN107836558A (zh) * | 2017-12-08 | 2018-03-27 | 北京龙诚健康大数据科技有限公司 | 一种降压降糖降尿酸抗肿瘤的红球藻压片糖果及应用 |
CN109315573A (zh) * | 2017-12-01 | 2019-02-12 | 天津地天科技发展有限公司 | 一种预防衰老保健食品或食品的制作工艺和配方 |
CN114271497A (zh) * | 2021-12-29 | 2022-04-05 | 中国水产科学研究院黄海水产研究所 | 一种能够降低血清中高尿酸水平的组合物及其应用 |
CN114642657A (zh) * | 2020-12-17 | 2022-06-21 | 陈福安 | 虾青素油溶口服液 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0799888A (ja) * | 1993-09-30 | 1995-04-18 | Food Design Gijutsu Kenkyu Kumiai | 濃縮ファフィア色素油を含有する油脂及び油脂加工食品 |
JP2002226368A (ja) * | 2001-02-02 | 2002-08-14 | Fuji Chem Ind Co Ltd | 赤血球の酸化的損傷抑制剤 |
CN101889614A (zh) * | 2010-07-02 | 2010-11-24 | 刘道鸣 | 强抗氧化食用油 |
CN101978975A (zh) * | 2010-11-16 | 2011-02-23 | 云南绿A生物工程有限公司 | 一种雨生红球藻提取物制剂、其制备方法和用途 |
CN103191089A (zh) * | 2013-03-29 | 2013-07-10 | 李树森 | 一种新型的虾青素保健酒及制备方法 |
CN103238867A (zh) * | 2013-05-13 | 2013-08-14 | 李树森 | 一种虾青素醋蛋液配方及制备方法 |
-
2013
- 2013-09-30 CN CN201310455832.8A patent/CN103504301A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0799888A (ja) * | 1993-09-30 | 1995-04-18 | Food Design Gijutsu Kenkyu Kumiai | 濃縮ファフィア色素油を含有する油脂及び油脂加工食品 |
JP2002226368A (ja) * | 2001-02-02 | 2002-08-14 | Fuji Chem Ind Co Ltd | 赤血球の酸化的損傷抑制剤 |
CN101889614A (zh) * | 2010-07-02 | 2010-11-24 | 刘道鸣 | 强抗氧化食用油 |
CN101978975A (zh) * | 2010-11-16 | 2011-02-23 | 云南绿A生物工程有限公司 | 一种雨生红球藻提取物制剂、其制备方法和用途 |
CN103191089A (zh) * | 2013-03-29 | 2013-07-10 | 李树森 | 一种新型的虾青素保健酒及制备方法 |
CN103238867A (zh) * | 2013-05-13 | 2013-08-14 | 李树森 | 一种虾青素醋蛋液配方及制备方法 |
Non-Patent Citations (3)
Title |
---|
何璞等: "虾青素的特性及其生产与应用研究", 《漯河职业技术学院学报》, vol. 11, no. 2, 15 March 2012 (2012-03-15), pages 70 - 72 * |
无: "痛风的治疗和预防", 《双足与保健》, 16 September 2010 (2010-09-16), pages 10 - 12 * |
武万强等: "虾青素生物功能的研究进展", 《农产品加工·学刊》, no. 9, 25 September 2012 (2012-09-25), pages 92 - 96 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104644798A (zh) * | 2014-12-30 | 2015-05-27 | 天津天狮生物发展有限公司 | 一种预防缓解痛风及改善高尿酸血症的中药组合物 |
CN105901176A (zh) * | 2016-04-15 | 2016-08-31 | 安徽华安食品有限公司 | 一种糖尿病人专用调和油及其制备方法 |
CN107006622A (zh) * | 2017-04-06 | 2017-08-04 | 山东海葵生物科技有限公司 | 一种养生食用油及其制备方法 |
CN109315573A (zh) * | 2017-12-01 | 2019-02-12 | 天津地天科技发展有限公司 | 一种预防衰老保健食品或食品的制作工艺和配方 |
CN107836558A (zh) * | 2017-12-08 | 2018-03-27 | 北京龙诚健康大数据科技有限公司 | 一种降压降糖降尿酸抗肿瘤的红球藻压片糖果及应用 |
CN114642657A (zh) * | 2020-12-17 | 2022-06-21 | 陈福安 | 虾青素油溶口服液 |
CN114271497A (zh) * | 2021-12-29 | 2022-04-05 | 中国水产科学研究院黄海水产研究所 | 一种能够降低血清中高尿酸水平的组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103504301A (zh) | 一种降压降糖降尿酸抗肿瘤的虾青素油的配方及制备方法 | |
Nabi et al. | Health benefits of carotenoids and potential application in poultry industry: A review | |
US6344214B1 (en) | Method for retarding and ameliorating fever blisters and canker sores | |
CN102113636A (zh) | 仿野生鱼中草药型饲料 | |
WO2012043808A1 (ja) | 熱ショックタンパク質発現誘導剤 | |
WO2014057493A1 (en) | Astaxanthin derivatives for heat stress prevention and treatment | |
CN105105132A (zh) | 能够提高免疫力的虾青素营养保健软胶囊及制备方法 | |
CN108391816A (zh) | 一种抗氧化保健胶囊的生产方法 | |
TWM604565U (zh) | 含瑪卡粉的產品 | |
CN101168051A (zh) | 海洋胶原肽作为制备抗氧化药物、保健食品、食品或化妆品的用途 | |
CN102783568A (zh) | 一种饲料添加剂 | |
Ferreira et al. | Therapeutic and toxicological effects of natural compounds: Data from HPV16-transgenic and ICR mice | |
CN1723806A (zh) | 鲑鱼白(大马哈鱼白)营养保健食品及制备工艺 | |
Li et al. | Temperature acclimation improves high temperature tolerance of rainbow trout (Oncorhynchus mykiss) by improving mitochondrial quality and inhibiting apoptosis in liver | |
CN104430143A (zh) | 一种低胆固醇、富胡萝卜素、富dha鸡蛋的生产方法 | |
JP6419620B2 (ja) | 肩こり及び/又は目の充血改善剤 | |
CN109452641A (zh) | 一种含有银杏的复合保健品 | |
Kaur et al. | A review on the role of nutrition in combating cancer | |
Sheikhzadeh et al. | Effects of green tea (Camellia sinensis) ethanolic extract on biochemical parameters and oxidative status in goldfish (Carassius auratus) | |
CN109315507A (zh) | 一种含虾青素保健食品的配方及制备方法 | |
CN115211562B (zh) | 一种美容养颜的中药花胶组合物及其制备方法 | |
CN102885293A (zh) | 一种螺旋藻保健食品及制备方法 | |
Constantinescu et al. | A young man with orange hands | |
Hidayat | Cancer Treatment in Islamic Traditional Medicine | |
CN106617082A (zh) | 一种能够养护心脏的功能性食品、制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DD01 | Delivery of document by public notice |
Addressee: Li Shusen Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140115 |